Delayed COVID-19 Respiratory Failure in Patients with Lymphoma on Rituximab-based Chemoimmunotherapy

Marc S. Hoffmann; Siddhartha Ganguly

doi:10.1016/j.clml.2021.02.009

Delayed COVID-19 Respiratory Failure in Patients with Lymphoma on Rituximab-based Chemoimmunotherapy

Marc S. Hoffmann, Siddhartha Ganguly

Houston Methodist

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

• COVID-19 can present with delayed onset of symptoms in patients with lymphoma receiving rituximab-based chemoimmunotherapy. • Despite delayed onset of symptoms with prolonged asymptomatic period, outcomes can be particularly severe, including respiratory failure, thrombotic complications, and death.

Original language	English (US)
Pages (from-to)	e548-e550
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	21
Issue number	6
DOIs	https://doi.org/10.1016/j.clml.2021.02.009
State	Published - Jun 2021

Keywords

COVID-19
Chemotherapy
Rituximab

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.clml.2021.02.009

Cite this

@article{85cc8be965924f33b0a12c7b31d581bc,

title = "Delayed COVID-19 Respiratory Failure in Patients with Lymphoma on Rituximab-based Chemoimmunotherapy",

abstract = "• COVID-19 can present with delayed onset of symptoms in patients with lymphoma receiving rituximab-based chemoimmunotherapy. • Despite delayed onset of symptoms with prolonged asymptomatic period, outcomes can be particularly severe, including respiratory failure, thrombotic complications, and death.",

keywords = "COVID-19, Chemotherapy, Rituximab",

author = "Hoffmann, {Marc S.} and Siddhartha Ganguly",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = jun,

doi = "10.1016/j.clml.2021.02.009",

language = "English (US)",

volume = "21",

pages = "e548--e550",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Delayed COVID-19 Respiratory Failure in Patients with Lymphoma on Rituximab-based Chemoimmunotherapy

AU - Hoffmann, Marc S.

AU - Ganguly, Siddhartha

PY - 2021/6

Y1 - 2021/6

N2 - • COVID-19 can present with delayed onset of symptoms in patients with lymphoma receiving rituximab-based chemoimmunotherapy. • Despite delayed onset of symptoms with prolonged asymptomatic period, outcomes can be particularly severe, including respiratory failure, thrombotic complications, and death.

AB - • COVID-19 can present with delayed onset of symptoms in patients with lymphoma receiving rituximab-based chemoimmunotherapy. • Despite delayed onset of symptoms with prolonged asymptomatic period, outcomes can be particularly severe, including respiratory failure, thrombotic complications, and death.

KW - COVID-19

KW - Chemotherapy

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=85102276395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85102276395&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2021.02.009

DO - 10.1016/j.clml.2021.02.009

M3 - Article

C2 - 33712408

AN - SCOPUS:85102276395

SN - 2152-2650

VL - 21

SP - e548-e550

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 6

ER -

Delayed COVID-19 Respiratory Failure in Patients with Lymphoma on Rituximab-based Chemoimmunotherapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this